Logo image of SRGA

SURGALIGN HOLDINGS INC (SRGA) Stock Fundamental Analysis

USA - NASDAQ:SRGA - US86882C2044 - Common Stock

0.1829 USD
-0.09 (-32.98%)
Last: 6/30/2023, 8:00:01 PM
0.1235 USD
-0.06 (-32.48%)
After Hours: 6/30/2023, 8:00:01 PM
Fundamental Rating

1

Taking everything into account, SRGA scores 1 out of 10 in our fundamental rating. SRGA was compared to 188 industry peers in the Health Care Equipment & Supplies industry. SRGA may be in some trouble as it scores bad on both profitability and health. SRGA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

SRGA had negative earnings in the past year.
In the past year SRGA has reported a negative cash flow from operations.
In the past 5 years SRGA always reported negative net income.
SRGA had negative operating cash flow in 4 of the past 5 years.
SRGA Yearly Net Income VS EBIT VS OCF VS FCFSRGA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 -50M -100M -150M -200M

1.2 Ratios

The profitability ratios for SRGA are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SRGA Yearly ROA, ROE, ROICSRGA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 200 -200 -400

1.3 Margins

SRGA's Gross Margin of 47.06% is in line compared to the rest of the industry. SRGA outperforms 43.00% of its industry peers.
SRGA's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for SRGA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 47.06%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-11.98%
GM growth 5Y-0.73%
SRGA Yearly Profit, Operating, Gross MarginsSRGA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 50 -50 -100 -150

2

2. Health

2.1 Basic Checks

SRGA does not have a ROIC to compare to the WACC, probably because it is not profitable.
SRGA has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, SRGA has a worse debt to assets ratio.
SRGA Yearly Shares OutstandingSRGA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M
SRGA Yearly Total Debt VS Total AssetsSRGA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 100M 200M 300M

2.2 Solvency

SRGA has an Altman-Z score of -14.39. This is a bad value and indicates that SRGA is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -14.39, SRGA is not doing good in the industry: 85.51% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -14.39
ROIC/WACCN/A
WACC5.62%
SRGA Yearly LT Debt VS Equity VS FCFSRGA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 2.67 indicates that SRGA has no problem at all paying its short term obligations.
SRGA's Current ratio of 2.67 is on the low side compared to the rest of the industry. SRGA is outperformed by 60.87% of its industry peers.
A Quick Ratio of 2.00 indicates that SRGA should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 2.00, SRGA is in line with its industry, outperforming 42.03% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.67
Quick Ratio 2
SRGA Yearly Current Assets VS Current LiabilitesSRGA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M 200M

2

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 50.34% over the past year.
SRGA shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -11.04%.
The Revenue for SRGA have been decreasing by -21.76% on average. This is quite bad
EPS 1Y (TTM)50.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.14%
Revenue 1Y (TTM)-11.04%
Revenue growth 3Y-11.28%
Revenue growth 5Y-21.76%
Sales Q2Q%-18.72%

3.2 Future

The Earnings Per Share is expected to decrease by -26.80% on average over the next years. This is quite bad
SRGA is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 5.28% yearly.
EPS Next Y-58.25%
EPS Next 2Y-26.8%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-37.13%
Revenue Next 2Y-17.44%
Revenue Next 3Y10.86%
Revenue Next 5Y5.28%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
SRGA Yearly Revenue VS EstimatesSRGA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M
SRGA Yearly EPS VS EstimatesSRGA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10 -20 -30

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SRGA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SRGA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SRGA Price Earnings VS Forward Price EarningsSRGA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SRGA Per share dataSRGA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 -10

4.3 Compensation for Growth

SRGA's earnings are expected to decrease with -26.80% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-26.8%
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

SRGA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

SURGALIGN HOLDINGS INC

NASDAQ:SRGA (6/30/2023, 8:00:01 PM)

After market: 0.1235 -0.06 (-32.48%)

0.1829

-0.09 (-32.98%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-11 2023-05-11/amc
Earnings (Next)08-07 2023-08-07/amc
Inst Owners0%
Inst Owner Change0%
Ins Owners110.88%
Ins Owner Change0%
Market Cap1.68M
Revenue(TTM)78.12M
Net Income(TTM)-50.49M
Analysts82
Price Target2.3 (1157.52%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)48.19%
Min EPS beat(2)34.2%
Max EPS beat(2)62.17%
EPS beat(4)4
Avg EPS beat(4)31.3%
Min EPS beat(4)12.05%
Max EPS beat(4)62.17%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)6.19%
Min Revenue beat(2)-3.37%
Max Revenue beat(2)15.74%
Revenue beat(4)1
Avg Revenue beat(4)0.19%
Min Revenue beat(4)-7.31%
Max Revenue beat(4)15.74%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-18.18%
EPS NQ rev (1m)-0.98%
EPS NQ rev (3m)36.11%
EPS NY rev (1m)-0.98%
EPS NY rev (3m)-47.17%
Revenue NQ rev (1m)0.98%
Revenue NQ rev (3m)-16.92%
Revenue NY rev (1m)0.98%
Revenue NY rev (3m)-37.79%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.02
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-5.81
EYN/A
EPS(NY)-11.27
Fwd EYN/A
FCF(TTM)-5.36
FCFYN/A
OCF(TTM)-4.57
OCFYN/A
SpS8.51
BVpS-0.97
TBVpS-0.97
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 47.06%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-11.98%
GM growth 5Y-0.73%
F-Score2
Asset Turnover1.15
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 341.79%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.67
Quick Ratio 2
Altman-Z -14.39
F-Score2
WACC5.62%
ROIC/WACCN/A
Cap/Depr(3y)371.14%
Cap/Depr(5y)257.39%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)50.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.14%
EPS Next Y-58.25%
EPS Next 2Y-26.8%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-11.04%
Revenue growth 3Y-11.28%
Revenue growth 5Y-21.76%
Sales Q2Q%-18.72%
Revenue Next Year-37.13%
Revenue Next 2Y-17.44%
Revenue Next 3Y10.86%
Revenue Next 5Y5.28%
EBIT growth 1Y-18.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-55.77%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y59.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y61.51%
OCF growth 3YN/A
OCF growth 5YN/A

SURGALIGN HOLDINGS INC / SRGA FAQ

Can you provide the ChartMill fundamental rating for SURGALIGN HOLDINGS INC?

ChartMill assigns a fundamental rating of 1 / 10 to SRGA.


Can you provide the valuation status for SURGALIGN HOLDINGS INC?

ChartMill assigns a valuation rating of 0 / 10 to SURGALIGN HOLDINGS INC (SRGA). This can be considered as Overvalued.


What is the profitability of SRGA stock?

SURGALIGN HOLDINGS INC (SRGA) has a profitability rating of 0 / 10.


Can you provide the financial health for SRGA stock?

The financial health rating of SURGALIGN HOLDINGS INC (SRGA) is 1 / 10.